Piraeus Medical has announced the US launch of the 6Fr 70 NeuGlide catheter alongside first clinical cases utilising the device following US Food and Drug Administration (FDA) clearance.
The 6Fr 70 NeuGlide expands Piraeus’s growing neurointerventional access portfolio, joining the 7Fr 87 NeuGlide+ and 8Fr 93 NeuFlex catheters. The company states that it now offers three catheter platforms backed by “one distinct approach” to catheter design.
Built on Piraeus’s patented, ‘linerless’ catheter construction, the 6Fr 70 NeuGlide is engineered to optimise inner diameter relative to outer diameter while combining distal flexibility with proximal support.
The addition of the 6Fr 70 NeuGlide represents another step in the company’s mission to “rethink neurovascular access” and give physicians new tools for navigating increasingly complex procedures, as noted in a Piraeus press release.
Following one of the first US cases with the 6Fr 70 NeuGlide catheter, Waleed Brinjikji (Mayo Clinic, Rochester, USA) said: “It was an honour to perform the first-in-human case with the new 6Fr NeuGlide from Piraeus. I haven’t seen anything like it, the proximal support and distal flexibility of the catheter allowed us to achieve the distal positioning necessary to successfully take down a complex dAVF [dural arteriovenous fistula], all through 6Fr access.”
